Position in FULC
as of Jun 30, 2026
· filed Jul 29, 2026
Position Value
$247,533
-$191,609 QoQ
Shares Held
67,632
-45.0% QoQ
Ownership
0.089%
of shares outstanding
% of Portfolio
0.00%
of 13F equity value
Holder Rank
#74
of 154 holders
Holding Since
Dec 2022
7 quarters on record
Voting authority
Sole 100%
Shared 0%
None 0%
Common Shares in FULC Over Time
Shares Held
Position Value (USD)
Position in Biotechnology
Healthcare · as of Jun 30, 2026ALPS ADVISORS INC holds $213,436,831 across 115 Biotechnology names. FULC ranks #109 (0.1% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | RPRX |
Royalty Pharma plc
|
315,335 | $17,680,833 | |
| 2 | APGE |
Apogee Therapeutics, Inc.
|
62,523 | $8,298,677 | |
| 3 | CGON |
CG Oncology, Inc.
|
89,218 | $6,338,938 | |
| 4 | XENE |
Xenon Pharmaceuticals Inc.
|
97,610 | $5,891,739 | |
| 5 | ORKA |
Oruka Therapeutics, Inc.
|
61,014 | $5,806,702 | |
| 6 | DNTH |
Dianthus Therapeutics, Inc. /DE/
|
55,281 | $5,388,791 | |
| 7 | TVTX |
Travere Therapeutics, Inc.
|
93,981 | $5,339,060 | |
| 8 | DFTX |
Definium Therapeutics, Inc.
|
110,388 | $5,192,651 |
All Filings in FULC
Export CSV
7 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-06-30 | $247,533 | 67,632 | Shares | Defined | 2026-07-29 | |
| 2024-09-30 | $439,142 | 123,009 | Shares | Defined | 2024-11-12 | |
| 2024-06-30 | $300,569 | 48,479 | Shares | Defined | 2024-08-13 | |
| 2024-03-31 | $412,358 | 43,682 | Shares | Defined | 2024-05-14 | |
| 2023-12-31 | $269,014 | 39,854 | Shares | Defined | 2024-02-14 | |
| 2023-03-31 | $115,972 | 40,692 | Shares | Defined | 2023-05-10 | |
| 2022-12-31 | $257,406 | 35,358 | Shares | Defined | 2023-02-14 | |
| No filing history on record for this holder in this stock. | ||||||